Alto Neuroscience, Inc. (ANRO) Financial Statements
$21.97NYSE: ANROMarket Cap $862.15M
Alto Neuroscience, Inc. most recently reported annual revenue of $0, a net loss of $63.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Alto Neuroscience, Inc.: net profit was positive in 0 of 5 reported years; the most recent year shows a net loss of $63.0M.
Income Statement — 5 Years (USD millions)
Metric
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
Operating Expenses
$12.0M
$29.0M
$38.0M
$69.0M
$66.0M
Operating Profit
$-12.0M
$-29.0M
$-38.0M
$-69.0M
$-66.0M
Operating Margin
-5740.9%
0.0%
0.0%
0.0%
0.0%
Other Income
$3.0M
$1.0M
$2.0M
$7.0M
$3.0M
Interest
$0
$0
$1.0M
$1.0M
$2.0M
Depreciation
$0
$0
$0
$1.0M
$1.0M
Profit Before Tax
$-9.0M
$-28.0M
$-36.0M
$-61.0M
$-63.0M
Tax
$0
$0
$0
$0
$0
Net Profit
$-9.0M
$-28.0M
$-36.0M
$-61.0M
$-63.0M
EPS
$-0.36
$-1.08
$-1.35
$-2.50
$-2.19
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
3 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$10.0M
$12.0M
$14.0M
$18.0M
$19.0M
$17.0M
$16.0M
$19.0M
$15.0M
$-116.0M
$27.0M
$29.0M
Operating Profit
$-10.0M
$-12.0M
$-14.0M
$-18.0M
$-19.0M
$-17.0M
$-16.0M
$-19.0M
$-15.0M
$116.0M
$-27.0M
$-29.0M
Operating Margin
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Interest
$0
$0
$0
$0
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$0
Profit Before Tax
$-9.0M
$-11.0M
$-13.0M
$-16.0M
$-17.0M
$-15.0M
$-15.0M
$-18.0M
$-14.0M
$-16.0M
$-26.0M
$-28.0M
Tax
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Profit
$-9.0M
$-11.0M
$-13.0M
$-16.0M
$-17.0M
$-15.0M
$-15.0M
$-18.0M
$-14.0M
$-16.0M
$-26.0M
$-28.0M
EPS
$-0.34
$-0.42
$-0.50
$-0.59
$-0.62
$-0.56
$-0.56
$-0.65
$-0.52
$-0.51
$-0.80
$-0.65
Over the 5 years reported for Alto Neuroscience, Inc., borrowings decreased from $38.0M in 2021 to $4.0M in 2025, cash stood at $176.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 16.18 times.
Balance Sheet — 5 Years (USD millions)
Metric
2021
2022
2023
2024
2025
Total Assets
$29.0M
$51.0M
$87.0M
$178.0M
$185.0M
Current Assets
$28.0M
$49.0M
$85.0M
$169.0M
$178.0M
Cash
$26.0M
$48.0M
$83.0M
$168.0M
$176.0M
Inventory
$0
$0
$0
$0
$0
Receivables
$2.0M
$1.0M
$0
$0
$0
Fixed Assets
$1.0M
$2.0M
$1.0M
$8.0M
$6.0M
Capital Work in Progress
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$1.0M
$1.0M
Other Assets
$0
$0
$0
$0
$0
Total Liabilities
$41.0M
$89.0M
$158.0M
$26.0M
$34.0M
Current Liabilities
$2.0M
$6.0M
$6.0M
$10.0M
$11.0M
Borrowings
$38.0M
$82.0M
$10.0M
$17.0M
$4.0M
Other Liabilities
$3.0M
$7.0M
$148.0M
$9.0M
$29.0M
Equity
$0
$0
$0
$0
$0
Reserves
$-12.0M
$-38.0M
$-72.0M
$151.0M
$151.0M
For Alto Neuroscience, Inc., operating cash flow was positive in 0 of 5 reported years; free cash flow in the latest year was negative at $52.0M; free cash flow was positive in 0 of 5 years.
Cash Flow Statement — 5 Years (USD millions)
Metric
2021
2022
2023
2024
2025
Operating Cash Flow
$-9.0M
$-20.0M
$-33.0M
$-47.0M
$-52.0M
Investing Cash Flow
$-1.0M
$-1.0M
$-1.0M
$-4.0M
$0
Financing Cash Flow
$0
$0
$-2.0M
$-3.0M
$0
Net Cash Flow
$22.0M
$23.0M
$34.0M
$86.0M
$8.0M
Free Cash Flow
$-10.0M
$-21.0M
$-34.0M
$-49.0M
$-52.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
1.96
EV / EBITDA
-7.47
FCF Yield
-8.14%
Quick Ratio
14.85
Interest Coverage
19.66
Return 1Y
774.59%
Return 3Y
—
Return 5Y
—
Alto Neuroscience, Inc. (ANRO) financials — frequently asked questions
What is Alto Neuroscience, Inc.'s annual revenue?
Alto Neuroscience, Inc. (ANRO) reported annual revenue of $0 in its most recent fiscal year.
What is Alto Neuroscience, Inc.'s net profit?
Alto Neuroscience, Inc. (ANRO) reported a net loss of $63.0M in its most recent fiscal year.
What is ANRO EV/EBITDA?
Alto Neuroscience, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -7.47. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.